12.5 Neonatal Sepsis, Congenital Infections & Neonatal Abstinence Syndrome (NAS/NOWS)
Key Takeaways
- Neonatal Sepsis Manifestations & Diagnostic Biomarkers: Early-Onset Sepsis (<72 hours, vertically transmitted GBS/E. coli) presents with subtle signs (hypothermia <36.5°C, tachypnea, poor feeding, lethargy); an Immature-to-Total neutrophil ratio (I:T ratio) ≥0.20 or absolute neutropenia strongly suggests bacterial infection, requiring pre-antibiotic blood cultures (≥1.0 mL).
- Empiric Antimicrobial Regimens: Standard empiric coverage for EOS is IV Ampicillin (covering GBS, Listeria, Enterococcus) plus IV Gentamicin (synergistic Gram-negative coverage for E. coli); Late-Onset Sepsis (LOS, >72 hr nosocomial/community) is treated with IV Vancomycin plus an aminoglycoside or expanded Gram-negative agent.
- Congenital TORCH Infections: Congenital Cytomegalovirus (CMV; most common) characteristically exhibits periventricular intracranial calcifications, microcephaly, sensorineural hearing loss, and blueberry muffin rash; Congenital Toxoplasmosis produces diffuse cortical calcifications, hydrocephalus, and chorioretinitis; Congenital Syphilis presents with copper-red maculopapular rash, palmar/plantar desquamation, and purulent "snuffles".
- Neonatal Herpes Simplex Virus (HSV): Acquired intrapartum and classified as Skin-Eye-Mouth (SEM), CNS encephalitis, or Disseminated multi-organ failure; any vesicular rash on an erythematous base warrants emergent isolation and high-dose intravenous Acyclovir (60 mg/kg/day divided q8h for 14–21 days) without awaiting viral culture results.
- Neonatal Opioid Withdrawal Syndrome (NOWS) & ESC Model: Prenatal opioid exposure leads to hyperadrenergic withdrawal across CNS, autonomic, and GI domains; the evidence-based Eat, Sleep, Console (ESC) model emphasizes non-pharmacologic interventions (rooming-in, skin-to-skin, quiet room, swaddling, frequent feeds) as first-line therapy, reserving oral morphine or methadone only for functional ESC failure.
Last updated: August 2026
Neonatal Sepsis: Early-Onset (EOS) vs. Late-Onset (LOS)
Neonatal sepsis is a systemic infection of bacterial, viral, or fungal origin occurring during the first 28 days of life, accompanied by hemodynamic and metabolic dysfunction. The neonate is exceptionally vulnerable to invasive infection due to developmental immune immaturity: deficient complement cascades, impaired polymorphonuclear leukocyte (neutrophil) chemotaxis and intracellular killing, and low circulating endogenous immunoglobulin levels (only maternal IgG is actively transported across the placenta after 32 weeks; endogenous IgM and IgA do not cross the placenta).
+---------------------------------------------------------------------------------------------------+
| NEONATAL SEPSIS: EOS VS. LOS DIFFERENTIATION |
+---------------------------------------------------------------------------------------------------+
Clinical Parameter Early-Onset Sepsis (EOS) Late-Onset Sepsis (LOS)
---------------------- ---------------------------------- ---------------------------------------
Timeline & Onset Occurs within first 72 hours of Occurs at ≥72 hours to 28 days
life (frequently within 24 hours). of life (peaks 10-21 days).
---------------------------------------------------------------------------------------------------
Transmission Route Vertical transmission from maternal Ascending or horizontal transmission
genital tract (intrapartum). from hospital or community environment.
---------------------------------------------------------------------------------------------------
Primary Pathogens 1. Group B Streptococcus (GBS / 1. Coagulase-Negative Staphylococci
Streptococcus agalactiae) 40-50% (CoNS / Staph epidermidis) ~50%.
2. Escherichia coli (30-40%; most 2. Staphylococcus aureus (MSSA / MRSA).
common in preterm infants). 3. Gram-Negative Bacilli (Klebsiella,
3. Listeria monocytogenes, Pseudomonas, Serratia, E. coli).
Enterococcus, H. influenzae. 4. Candida albicans (preterm / TPN / lines).
---------------------------------------------------------------------------------------------------
Major Risk Factors • Inadequate maternal GBS intra- • Extreme prematurity / VLBW (<1,500 g).
partum antibiotic prophylaxis. • Central vascular lines (UVC, PICC).
• Clinical Chorioamnionitis • Endotracheal mechanical ventilation.
(Maternal fever ≥39.0°C or • Total Parenteral Nutrition (TPN) / Lipids.
≥38.0°C with purulent fluid, • Delayed enteral feeding / Prolonged
fetal/maternal tachycardia). broad-spectrum antibiotic exposure.
• Prolonged ROM (≥18 hours).
• Preterm labor (<37 weeks).
+---------------------------------------------------------------------------------------------------+
Clinical Presentation, Diagnostic Biomarkers & Antibiotic Regimens
The clinical presentation of neonatal sepsis is notoriously subtle, non-specific, and easily overlooked. Bedside perinatal nurses must maintain an exceptionally high index of suspicion for the "Rule of Subtle Signs."
+---------------------------------------------------------------------------------------------------+
| CLINICAL MANIFESTATIONS OF NEONATAL SEPSIS |
+---------------------------------------------------------------------------------------------------+
System Early & Subtle Physical Findings
---------------------- ---------------------------------------------------------------------------
Thermoregulation • Temperature Instability: HYPOTHERMIA (<36.5°C / 97.7°F) is more frequent
and clinically ominous than fever (>37.5°C), especially in preterm infants.
---------------------------------------------------------------------------------------------------
Cardiorespiratory • Tachypnea (RR >60), persistent grunting, mild nasal flaring, retractions.
• Apnea (>20 seconds) or sudden increase in periodic breathing episodes.
• Tachycardia (>160 bpm) or unexplained bradycardia (<100 bpm).
• Delayed capillary refill (>3 seconds), pallor, cutaneous mottling, hypotension.
---------------------------------------------------------------------------------------------------
Neuromuscular • Lethargy, decreased spontaneous movement, hypotonia ("floppiness").
• Irritability, high-pitched cry, weak suck, hyporeflexia.
• Full or bulging anterior fontanelle, seizures (suggesting meningitis).
---------------------------------------------------------------------------------------------------
Gastrointestinal • Poor feeding, refusal to suck, increased gastric residuals, vomiting,
abdominal distention, bilious aspirates, diarrhea.
---------------------------------------------------------------------------------------------------
Integumentary • Petechiae, purpura, sclerema (waxy skin induration), jaundice.
+---------------------------------------------------------------------------------------------------+
Diagnostic Biomarkers & Laboratory Evaluation
- Blood Culture: The definitive gold standard. A minimum volume of $1.0\text{ mL}$ of blood must be collected under strict sterile skin antisepsis prior to initiating antibiotics.
- Complete Blood Count & Immature-to-Total (I:T) Ratio: Leukopenia ($WBC <5,000\text{/mcL}$) is significantly more predictive of sepsis than leukocytosis. Neutropenia ($ANC <1,000\text{--}1,500\text{/mcL}$) indicates bone marrow depletion. The Immature-to-Total (I:T) Neutrophil Ratio is the most sensitive hematologic marker: An $\text{I:T Ratio} \ge 0.20$ (20%) strongly suggests neonatal bacterial infection.
- Lumbar Puncture (LP): Mandatory when blood culture is positive, clinical status deteriorates, or meningitis is suspected. CSF findings in bacterial meningitis: elevated WBC count ($>20\text{--}30\text{ cells/mcL}$ with neutrophil predominance), elevated protein ($>150\text{--}170\text{ mg/dL}$), and decreased glucose ($<50%$ of simultaneous blood glucose).
+---------------------------------------------------------------------------------------------------+
| EMPIRIC ANTIMICROBIAL REGIMENS FOR NEONATAL SEPSIS |
+---------------------------------------------------------------------------------------------------+
[ 1. EARLY-ONSET SEPSIS (EOS) EMPIRIC BUNDLE ]
• INTRAVENOUS AMPICILLIN (50-100 mg/kg/dose IV q12h):
Provides bactericidal coverage for Group B Streptococcus (GBS), Listeria monocytogenes,
and susceptible Enterococcus species.
• PLUS INTRAVENOUS GENTAMICIN (4-5 mg/kg/dose IV q24-36h):
Aminoglycoside providing synergy and potent Gram-negative coverage against Escherichia coli,
Klebsiella, and Pseudomonas. (Monitor peak and trough levels; risk of oto/nephrotoxicity).
• Note: Cefotaxime is avoided for routine empiric use to prevent emergence of ESBL pathogens
and invasive candidiasis, except when documented Gram-negative meningitis is present.
│
▼
[ 2. LATE-ONSET SEPSIS (LOS) EMPIRIC BUNDLE ]
• INTRAVENOUS VANCOMYCIN (10-15 mg/kg/dose IV q8-18h):
Covers Coagulase-Negative Staphylococci (CoNS) and Methicillin-Resistant S. aureus (MRSA).
• PLUS INTRAVENOUS AMINOGLYCOSIDE (Gentamicin/Amikacin) OR CEFEPIME / MEROPENEM:
Provides expanded broad-spectrum coverage for nosocomial Gram-negative enteric bacilli.
TORCH & Congenital Viral Infections
The TORCH complex encompasses congenital infections that cross the placenta to produce characteristic multisystem anomalies in the developing fetus.
+---------------------------------------------------------------------------------------------------+
| TORCH CONGENITAL INFECTION DIFFERENTIATION |
+---------------------------------------------------------------------------------------------------+
Pathogen & Transmission Classic Clinical Triad & Physical Manifestations
---------------------------- ---------------------------------------------------------------------
[ T ] Toxoplasmosis • Maternal ingestion of undercooked cyst meat or cat feces.
(Toxoplasma gondii) • CLASSIC TRIAD: Chorioretinitis, Hydrocephalus, and Diffuse
Intracranial Calcifications (scattered throughout cortex).
• Microcephaly, convulsions, maculopapular rash, hepatomegaly.
• Treatment: Pyrimethamine, sulfadiazine, and folinic acid.
---------------------------------------------------------------------------------------------------
[ O ] Other: Congenital • Maternal spirochete transmission across placenta.
Syphilis • EARLY SIGNS (<2 yr): Copious purulent/bloody rhinitis ("THE SNUFFLES"),
(Treponema pallidum) copper-colored maculopapular rash on PALMS & SOLES with desquamation,
hepatosplenomegaly, jaundice, osteochondritis (Wimberger sign).
• LATE SIGNS (>2 yr): Hutchinson teeth, interstitial keratitis, CN VIII
deafness, saber shins, saddle nose deformity.
• Treatment: IV Aqueous Crystalline Penicillin G for 10 days.
---------------------------------------------------------------------------------------------------
[ R ] Rubella Virus • Primary maternal infection in first trimester.
(German Measles) • CLASSIC GREGG TRIAD: Sensorineural Hearing Loss (most common),
Congenital Cataracts / Microphthalmia, and Congenital Heart Defects
(Patent Ductus Arteriosus / Peripheral Pulmonary Artery Stenosis).
• Integument: "Blueberry Muffin" Rash (dermal erythropoiesis).
---------------------------------------------------------------------------------------------------
[ C ] Cytomegalovirus (CMV) • MOST COMMON CONGENITAL VIRAL INFECTION WORLDWIDE.
(Human Herpesvirus 5) • CLASSIC HALLMARKS: Microcephaly, PERIVENTRICULAR INTRACRANIAL
CALCIFICATIONS (lining the lateral ventricles), Sensorineural
Hearing Loss (leading non-genetic cause of childhood deafness),
Chorioretinitis, Hepatosplenomegaly, Thrombocytopenic purpura.
• Diagnosis: Urine or saliva CMV PCR within first 2-3 weeks of life.
• Treatment: Oral Valganciclovir or IV Ganciclovir for 6 months.
---------------------------------------------------------------------------------------------------
[ H ] Herpes Simplex Virus • 85% intrapartum transmission during delivery via genital lesions.
(HSV-1 / HSV-2) • THREE CLINICAL SYNDROMES:
1. Skin, Eye, Mouth (SEM): Vesicular cluster lesions, keratitis.
2. CNS Disease: Temporal lobe encephalitis, seizures, lethargy.
3. Disseminated Disease: Septic shock, fulminant hepatitis, DIC.
• TREATMENT: High-Dose IV ACYCLOVIR (60 mg/kg/day divided q8h x 14-21d).
+---------------------------------------------------------------------------------------------------+
Neonatal Opioid Withdrawal Syndrome (NOWS / NAS)
Neonatal Opioid Withdrawal Syndrome (NOWS), a subcategory of Neonatal Abstinence Syndrome (NAS), occurs when chronic in-utero exposure to maternal opioids (heroin, methadone, buprenorphine, oxycodone, fentanyl) or non-opioids (benzodiazepines, SSRIs, gabapentinoids) is abruptly terminated at delivery following umbilical cord clamping.
Pathophysiology & Timing of Withdrawal
Opioids cross the placenta and bind to fetal central nervous system $\mu$-opioid receptors. Abrupt drug cessation removes inhibitory tone, triggering an uncontrolled, massive hyperadrenergic surge of norepinephrine, dopamine, serotonin, and acetylcholine.
- Short-acting opioids (Heroin, oxycodone): Withdrawal manifests within 24 to 48 hours of birth.
- Long-acting opioids (Methadone, Buprenorphine): Withdrawal onset is delayed, peaking between 48 to 72 hours and occasionally presenting as late as 5 to 7 days of life. Hospital observation for at least 4 to 7 days is mandatory.
+---------------------------------------------------------------------------------------------------+
| TRI-DOMAIN CLINICAL MANIFESTATIONS OF NOWS |
+---------------------------------------------------------------------------------------------------+
Domain Clinical Signs & Withdrawal Symptoms
---------------------- ---------------------------------------------------------------------------
Central Nervous System • High-pitched, inconsolable, shrill, continuous crying.
Hyperirritability • Coarse tremors at rest and with minimal stimulation; myoclonic jerks.
• Marked hypertonia, exaggerated Moro reflex, motor restlessness.
• Sleep fragmentation: Inability to sleep >1 hour between feedings.
• Severe neuro-irritability: Generalized seizures (2-5% of cases).
---------------------------------------------------------------------------------------------------
Autonomic Nervous • Temperature instability / fever; excessive sweating and diaphoresis.
System Instability • Frequent yawning (>3-4 consecutive episodes); frequent sneezing (>3-4 in a row).
• Nasal stuffiness, rhinorrhea, tachypnea (RR >60 breaths/min), skin mottling.
---------------------------------------------------------------------------------------------------
Gastrointestinal • Uncoordinated, frantic, disorganized suck; poor suck-swallow coordination.
Dysfunction • Voracious appetite paired with poor weight gain or excessive loss (>10%).
• Frequent regurgitation, projectile vomiting, watery explosive diarrhea.
• Severe perianal skin excoriation from acidic, loose stools.
+---------------------------------------------------------------------------------------------------+
Assessment Models: Finnegan vs. Eat, Sleep, Console (ESC)
Historically, the Modified Finnegan Neonatal Abstinence Scoring System (FNASS) used a 21-item weighted scoring rubric assessed every 3 to 4 hours. A Finnegan score $\ge 8$ on three consecutive checks or $\ge 12$ on two consecutive checks triggered pharmacotherapy. However, Finnegan scoring overweights benign autonomic signs (sneezing, yawning), leading to unnecessary opioid medication and prolonged NICU stays.
The Eat, Sleep, Console (ESC) Model (Current National Standard)
The Eat, Sleep, Console (ESC) approach evaluates the functional impact of withdrawal on the newborn rather than tabulating isolated physical signs. It prioritizes non-pharmacological care and keeps the mother-infant dyad together.
+---------------------------------------------------------------------------------------------------+
| THE EAT, SLEEP, CONSOLE (ESC) EVALUATION CRITERIA |
+---------------------------------------------------------------------------------------------------+
Core Function Objective Clinical Standard & Passing Criteria
---------------------- ---------------------------------------------------------------------------
[ E ] - EAT Is the infant able to eat adequately for gestational age?
• Bottle-feeding: Consumes ≥1 ounce (30 mL) per feeding.
• Breastfeeding: Latches and nurses effectively for ≥10 minutes per feed.
---------------------------------------------------------------------------------------------------
[ S ] - SLEEP Can the infant sleep uninterrupted for ≥1 hour after a feeding?
(Reflects autonomic and CNS stability).
---------------------------------------------------------------------------------------------------
[ C ] - CONSOLE Can the crying infant be consoled within 10 minutes using standard
soothing measures (swaddling, holding, skin-to-skin, pacifier)?
+---------------------------------------------------------------------------------------------------+
Non-Pharmacological Care Bundle (The Universal Foundation)
Non-pharmacological management must be maximized for all infants before considering pharmacotherapy:
- Continuous Rooming-In & Parental Presence: Keeping mother and infant together is the single most effective intervention to reduce withdrawal severity and decrease medication needs.
- Skin-to-Skin Contact (Kangaroo Care): Directly calms hyperadrenergic surges, stabilizes heart rate and temperature, and improves sleep duration.
- Low-Stimulation Environment: Dim lighting, quiet private room, minimal clustering of intrusive care, slow and gentle handling.
- Therapeutic Swaddling & Flexed Containment: Swaddling infant with hands positioned near the face supports self-soothing and suppresses startle-induced awakening.
- High-Calorie Enteral Feeding: Small, frequent feedings ($22\text{--}24\text{ kcal/oz}$ formula or maternal breast milk). Breastfeeding is strongly supported if the mother is enrolled in a stable, compliant substance use treatment program without illicit drug use.
- Perianal Skin Care: Apply thick barrier zinc oxide ointments generously with every diaper change to prevent excoriation from acidic, loose stools.
Pharmacotherapy Escalation Protocols
When an infant fails the ESC assessment (cannot eat $\ge 1\text{ oz}$, cannot sleep $\ge 1\text{ hr}$, or cannot be consoled within 10 minutes) despite maximal non-pharmacological support:
- First-Line Opioid Replacement: Oral Morphine Solution ($0.05\text{--}0.2\text{ mg/kg/dose}$ q3–4h) OR Oral Methadone ($0.05\text{--}0.1\text{ mg/kg/dose}$ q6–12h), titrated to achieve functional stability and weaned by 10% to 20% daily.
- Second-Line Adjunctive Agents (Polysubstance / Sedative Exposure):
- Clonidine (0.5–1.0 mcg/kg/dose q4–6h): Alpha-2 adrenergic agonist; suppresses central sympathetic outflow (sweating, tachycardia, hypertension, diarrhea). Monitor for bradycardia and hypotension.
- Phenobarbital: First-line adjunct for non-opioid withdrawal (sedative-hypnotics, barbiturates, polysubstance) or refractory seizures.
Loading diagram...
Test Your Knowledge
A 12-hour-old term infant born to a mother with suspected chorioamnionitis and prolonged rupture of membranes (22 hours) displays an axillary temperature of 36.1°C (97.0°F), respiratory rate of 68 breaths/min, and poor feeding. The complete blood count reveals a total white blood cell count of 4,200/mcL with 35% segmented neutrophils and 15% band forms. What is the calculated I:T ratio, and what is the nurse's immediate priority action?
A
B
C
D
Test Your Knowledge
A newborn is evaluated in the nursery for microcephaly, hepatosplenomegaly, and a petechial 'blueberry muffin' skin rash. Head ultrasonography demonstrates prominent periventricular intracranial calcifications lining the lateral ventricles, and an auditory brainstem response test reveals bilateral sensorineural hearing loss. Which congenital TORCH infection is most consistent with these findings?
A
B
C
D
Test Your Knowledge
A 9-day-old infant delivered vaginally presents with clustered vesicular lesions on an erythematous base on the scalp, conjunctival injection with serous drainage, and progressive lethargy. What is the nurse's priority clinical intervention?
A
B
C
D
Test Your Knowledge
A 2-day-old term infant born to a mother maintained on buprenorphine during pregnancy displays coarse tremors, frequent sneezing, and tachypnea. Using the Eat, Sleep, Console (ESC) model, the nurse notes the infant breastfeeds vigorously for 15 minutes, sleeps for 90 minutes between feeds, and is easily soothed within 3 minutes by parental swaddling and skin-to-skin contact. What is the most appropriate management plan?
A
B
C
D